Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Taiwan study tracks best biologic for psoriasis

NCT ID NCT04818385

Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study followed 240 adults in Taiwan with moderate-to-severe plaque psoriasis to see how well risankizumab works compared to other biologics in real-world settings. Participants received their prescribed treatment and were monitored for about 2 years. The main goal was to measure how many achieved at least 90% clearer skin (PASI 90).

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
risankizumab and other biologics
What this could lead to
If successful, this study could provide real-world evidence on which biologic works best for psoriasis patients in Taiwan, helping doctors choose more effective treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not test a new drug or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

240 people

The number who actually took part.

Started

May 2021

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with moderate to severe plaque psoriasis.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist t at the time of recruitment. * Initiating an approved biologic treatment for psoriasis as per regulatory and reimbursement policy in Taiwan. Physician's decision with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study. * Treatments prescribed in accordance to both the product monograph, regulatory and reimbursement policies in Taiwan. Exclusion Criteria: \- Participation in an interventional clinical trial, concurrently or within the last 30 days. Participation in another PMOS or Registry is acceptable.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

Contacts and locations

Locations

  • China Medical University Hospital /ID# 229961

    Taichung, 40447, Taiwan

  • Hualien Tzu Chi Hospital /ID# 238431

    Hualien City, 97002, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 230016

    Kaohsiung City, 807, Taiwan

  • Linkou Chang Gung Memorial Hospital /ID# 253775

    Taoyuan City, 333, Taiwan

  • National Cheng Kung University Hospital /ID# 253776

    Tainan, 704, Taiwan

  • National Taiwan University Hospital - Hsinchu branch /ID# 238432

    Hsinchu, 30059, Taiwan

  • National Taiwan University Hospital /ID# 230017

    Taipei City, Taipei, 100, Taiwan

  • Taipei Medical University Hospital /ID# 230018

    Taipei, 11031, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.